BioNTech Sets March 10, 2026, for Q4 and Full-Year 2025 Earnings Release
Event summary
- BioNTech will release Q4 and full-year 2025 financial results on March 10, 2026.
- A conference call and webcast will be held at 8:00 a.m. ET (1:00 p.m. CET) to discuss results and provide a corporate update.
- The company will host a replay of the webcast for 30 days post-call.
- BioNTech's diversified portfolio includes mRNA cancer immunotherapies, immunomodulators, and targeted therapies like ADCs and CAR-T treatments.
- The company collaborates with multiple global pharmaceutical partners, including Pfizer and Bristol Myers Squibb.
The big picture
BioNTech's upcoming earnings release comes at a critical juncture as the company shifts focus from COVID-19 vaccines to a broader portfolio of cancer and infectious disease therapies. The strategic partnerships with major pharmaceutical players will be key in determining its ability to scale innovations and maintain market relevance. Investors will be watching closely for signs of sustainable revenue growth beyond pandemic-era highs.
What we're watching
- Financial Performance
- How BioNTech's Q4 and full-year 2025 results will reflect its ongoing transition from pandemic-driven revenue to a diversified oncology and infectious disease pipeline.
- Pipeline Progress
- Whether the company's advancements in mRNA-based therapies and collaborations will drive near-term growth.
- Market Positioning
- The pace at which BioNTech can solidify its leadership in next-generation immunotherapy amid increasing competition.
Related topics